Biocardia announces fda market clearance of morph® dna™ steerable introducer product family

Sunnyvale, calif., aug. 29, 2024 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the food and drug administration (fda) has cleared biocardia to market the morph dna steerable introducer product family, subject to the general controls provisions of the federal food, drug, and cosmetic act.
BCDA Ratings Summary
BCDA Quant Ranking